Diagnostic and Therapeutic Gateways Open Simultaneously

The U.S. Food and Drug Administration (FDA) expanded approval on August 25, 2026, for Roche Holding AG (RHHBY)'s PATHWAY anti-HER2/neu 4B5 antibody test and VENTANA HER2 Dual ISH DNA Probe Cocktail as companion diagnostics for Ziihera prescriptions. The two tests use immunohistochemistry (IHC) and in situ hybridization (ISH) to assess HER2 protein expression and gene amplification. On the same day, Jazz Pharmaceuticals plc (JAZZ)'s Ziihera (zanidatamab-hrii), a bispecific antibody targeting two distinct HER2 epitopes, received formal approval for first-line treatment of unresectable locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The simultaneous approval of the therapy and diagnostic test reduces bottlenecks from pathology to prescription, enabling patient access immediately after launch.

Phase 3 Results Reshape First-Line Treatment Competition

The approval is based on HERIZON-GEA-01 (NCT05152147), a global randomized, open-label, active-controlled Phase 3 trial. In patients with HER2 IHC 3+, the median progression-free survival (mPFS) for Ziihera combined with fluoropyrimidine and platinum chemotherapy was 14.2 months, compared to 7.6 months for trastuzumab and chemotherapy, with a hazard ratio (HR) of 0.55. The FDA approved Ziihera plus chemotherapy for IHC 3+ patients and Ziihera plus Tevimbra (tislelizumab-jsgr, PD-1) plus chemotherapy for IHC 3+ or IHC 2+/ISH+ patients as first-line treatments. This creates HER2-based treatment options independent of PD-L1 expression, broadening the competitive landscape in the HER2-PD-1 combination market.

Standard of Care and ADCs Compete in the Commercial Market

The current U.S. first-line standard is Merck & Co. (MRK)'s Keytruda (pembrolizumab, PD-1), Roche's Herceptin (trastuzumab, HER2), and chemotherapy, which received formal FDA approval on March 19, 2025, for patients with PD-L1 CPS ≥1. In later-line treatment, AstraZeneca plc (AZN) and Daiichi Sankyo Co., Ltd. (4568.T)'s Enhertu (fam-trastuzumab deruxtecan-nxki, HER2 antibody-drug conjugate) has been used since January 15, 2021, in patients previously treated with trastuzumab. The HER2-positive gastric and gastroesophageal junction cancer market in the seven major markets is projected to grow from $720 million in 2025 to $2.318 billion in 2034. Roche's test, which standardizes IHC and ISH pathways and includes esophageal adenocarcinoma, serves as a foundation for increasing Ziihera's prescription conversion rate and diagnostic consumable demand.

Platform Validation and Contract Value Realization

Ziihera received FDA accelerated approval on November 20, 2024, for previously treated HER2 IHC 3+ biliary tract cancer patients and has now expanded to first-line gastroesophageal adenocarcinoma. Zymeworks Inc. (ZYME) developed Ziihera using its Azymetric bispecific antibody platform, and Jazz secured development and commercialization rights in most regions outside of Asia-Pacific. The 2022 agreement included an upfront payment of $50 million, option exercise fees of up to $325 million, regulatory milestones of up to $525 million, and commercial milestones of up to $862.5 million, with royalty rates ranging from 10% to 20%. This FDA approval triggers a $250 million milestone payment, strengthening Zymeworks' unlevered cash flow and adding a major indication to Jazz's late-stage oncology asset portfolio.